Urological cancer: Time for another rethink on prostate cancer screening.

Urological cancer: Time for another rethink on prostate cancer screening.

Opis bibliograficzny
Główni autorzy:	Vickers, A, Lilja, H
Format:	Journal article
Język:	English
Wydane:	2012

Podobne zapisy

Screening for prostate cancer.
od: Carlsson, S, i wsp.
Wydane: (2012)

Prostate cancer: estimating the benefits of PSA screening.
od: Vickers, A, i wsp.
Wydane: (2009)

Screening for prostate cancer: To the editor
od: Carlsson, S, i wsp.
Wydane: (2012)

Screening for prostate cancer: early detection or overdetection?
od: Vickers, A, i wsp.
Wydane: (2012)

Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening.
od: Savage, C, i wsp.
Wydane: (2010)

Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.
od: Lilja, H, i wsp.
Wydane: (2008)

Lead time associated with screening for prostate cancer.
od: Törnblom, M, i wsp.
Wydane: (2004)

Screening for prostate cancer: an update.
od: Shariat, S, i wsp.
Wydane: (2008)

Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer.
od: Vickers, A, i wsp.
Wydane: (2009)

Five genetic variants associated with prostate cancer.
od: Vickers, A, i wsp.
Wydane: (2008)

Predicting prostate cancer many years before diagnosis: how and why?
od: Vickers, A, i wsp.
Wydane: (2012)

Prostate-specific antigen and prostate cancer: Prediction, detection and monitoring (Corrigendum) (Nature Reviews Cancer (2008) 8, (268-278))
od: Lilja, H, i wsp.
Wydane: (2008)

A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam.
od: Vickers, A, i wsp.
Wydane: (2010)

Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden.
od: Vickers, A, i wsp.
Wydane: (2010)

We need a better marker for prostate cancer. How about renaming PSA?
od: Vickers, A, i wsp.
Wydane: (2012)

On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer.
od: Bangma, C, i wsp.
Wydane: (2010)

The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologically-based screening strategy.
od: Vickers, A, i wsp.
Wydane: (2007)

An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.
od: Vickers, A, i wsp.
Wydane: (2011)

Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review.
od: Carlsson, S, i wsp.
Wydane: (2012)

Cervical cancer screening in Switzerland: time to rethink the guidelines
od: Pierre Vassilakos, i wsp.
Wydane: (2015-02-01)

A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden.
od: Vickers, A, i wsp.
Wydane: (2008)

Finasteride to prevent prostate cancer: should all men or only a high-risk subgroup be treated?
od: Vickers, A, i wsp.
Wydane: (2010)

Tumor markers in prostate cancer I: blood-based markers.
od: Shariat, S, i wsp.
Wydane: (2011)

Prostate cancer screening in Switzerland: a literature review and consensus statement from the Swiss Society of Urology
od: Christoph Würnschimmel, i wsp.
Wydane: (2024-05-01)

A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands.
od: Gupta, A, i wsp.
Wydane: (2010)

The continuing role of prostate-specific antigen as a marker for localized prostate cancer: 'do not throw the baby out with the bath water'.
od: Challacombe, B, i wsp.
Wydane: (2009)

A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France.
od: Benchikh, A, i wsp.
Wydane: (2010)

Erratum: PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: Results from the European randomized study of screening for prostate cancer, Sweden section (International Journal of Cancer (2007) 120, (170-174))
od: Khatami, A, i wsp.
Wydane: (2007)

Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication.
od: Vickers, A, i wsp.
Wydane: (2010)

A blind spot in urology: Prostate cancer associated retinopathy
od: Catriona Duncan, i wsp.
Wydane: (2019-05-01)

PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section.
od: Khatami, A, i wsp.
Wydane: (2007)

A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden
od: Scardino Peter T, i wsp.
Wydane: (2008-07-01)

Rethinking euthanasia in the Indian context: Another perspective
od: Raghvendra S Shekhawat, i wsp.
Wydane: (2023-01-01)

Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.
od: Lilja, H, i wsp.
Wydane: (2007)

Urological education: Do we need a rethink?
od: Rajeev Kumar
Wydane: (2015-01-01)

Clinical translational research of liquid biopsy applications in prostate cancer and other urological cancers
od: Jingyi Huang, i wsp.
Wydane: (2023-01-01)

Circulating biomarkers for prostate cancer.
od: Steuber, T, i wsp.
Wydane: (2007)

Risk of dying from prostate cancer in men randomized to screening: differences between attendees and nonattendees.
od: Bergdahl, A, i wsp.
Wydane: (2009)

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer
od: Becker, C, i wsp.
Wydane: (2003)

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer.
od: Becker, C, i wsp.
Wydane: (2003)